Complimentary electrostatics dominate T-cell receptor binding to a psoriasis-associated peptide antigen presented by human leukocyte antigen C∗06:02
Journal of Biological Chemistry · 2023-07 · 299 (7) · 104930
DOI: 10.1016/j.jbc.2023.104930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023-07. Verfasst von Sushma Anand und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victo…. Hauptthemen laut MEDLINE: HLA-C Antigens, Psoriasis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, National Health and Medical Research Council, National Psoriasis Foundation.
Abstract (Originalsprache)
Psoriasis is a chronic skin disease characterized by hyperproliferative epidermal lesions infiltrated by autoreactive T cells. Individuals expressing the human leukocyte antigen (HLA) C∗06:02 allele are at highest risk for developing psoriasis. An autoreactive T cell clone (termed Vα3S1/Vβ13S1) isolated from psoriatic plaques is selective for HLA-C∗06:02, presenting a peptide derived from the melanocyte-specific autoantigen ADAMTSL5 (VRSRRCLRL). Here we determine the crystal structure of this psoriatic TCR-HLA-C∗06:02 ADAMTSL5 complex with a stabilized peptide. Docking of the TCR involves an extensive complementary charge network formed between negatively charged TCR residues interleaving with exposed arginine residues from the self-peptide and the HLA-C∗06:02 α1 helix. We probed these interactions through mutagenesis and activation assays. The charged interface spans the polymorphic region of the C1/C2 HLA group. Notably the peptide-binding groove of HLA-C∗06:02 appears exquisitely suited for presenting highly charged Arg-rich epitopes recognized by this acidic psoriatic TCR. Overall, we provide a structural basis for understanding the engagement of melanocyte antigen-presenting cells by a TCR implicated in psoriasis while simultaneously expanding our knowledge of how TCRs engage HLA-C.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
- Janssen Research & Development, LLC, Philadelphia, Pennsylvania, USA.
- Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia; Institute of Infection and Immunity, School of Medicin…
Förderung
- Australian Research Council
- National Health and Medical Research Council
- National Psoriasis Foundation
Zitieren
APA
Anand, S., Littler, D. R., Mobbs, J. I., Braun, A., Baker, D. G., Tennant, L., Purcell, A. W., Vivian, J. P., & Rossjohn, J. (2023). Complimentary electrostatics dominate T-cell receptor binding to a psoriasis-associated peptide antigen presented by human leukocyte antigen C∗06:02. Journal of Biological Chemistry, 299(7), 104930. https://doi.org/10.1016/j.jbc.2023.104930
Vancouver
Anand S, Littler DR, Mobbs JI, Braun A, Baker DG, Tennant L, et al. Complimentary electrostatics dominate T-cell receptor binding to a psoriasis-associated peptide antigen presented by human leukocyte antigen C∗06:02. Journal of Biological Chemistry. 2023;299(7):104930. doi:10.1016/j.jbc.2023.104930
BibTeX
@article{Anand2023,
author = {Anand, Sushma and Littler, Dene R and Mobbs, Jesse I and Braun, Asolina and Baker, Daniel G and Tennant, Luke and Purcell, Anthony W and Vivian, Julian P and Rossjohn, Jamie},
title = {Complimentary electrostatics dominate T-cell receptor binding to a psoriasis-associated peptide antigen presented by human leukocyte antigen C∗06:02},
journal = {Journal of Biological Chemistry},
year = {2023},
volume = {299},
number = {7},
pages = {104930},
doi = {10.1016/j.jbc.2023.104930}
}
EUVIMED